LianBio, a biopharmaceutical company, is developing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. It is developing "mavacamten" for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction, TP-03 for the treatment of Demodex blepharitis, and NBTXR3 for the treatment of head and neck squamous cell carcinoma and solid tumors, Infigratinib for the treatment of second-line and first-line cholangiocarcinoma and gastric cancers. LianBio was incorporated in 2019 and is headquartered in Princeton, NJ.
What is Lianbio's quote symbol?
What is the 52 week high and low for Lianbio (NASDAQ: LIAN)?
How much is Lianbio stock worth today?
How much is Lianbio's stock price per share?
What is Lianbio's Market Cap?